🇺🇸 FDA
Pipeline program

Zometa 4 mg/100 ml solution for infusion, XGEVA 120 mg solution for injection in pre-filled syringe

ZOSTER ICO-N-2018-14

Phase 3 small_molecule active

Quick answer

Zometa 4 mg/100 ml solution for infusion, XGEVA 120 mg solution for injection in pre-filled syringe for Patients, men or women over 18 old, with inoperable vertebral bone metastases who must beneficit treatment with stereotactic radiotherapy is a Phase 3 program (small_molecule) at CERO THERAPEUTICS HOLDINGS, INC. with 1 ClinicalTrials.gov record(s).

Program details

Company
CERO THERAPEUTICS HOLDINGS, INC.
Indication
Patients, men or women over 18 old, with inoperable vertebral bone metastases who must beneficit treatment with stereotactic radiotherapy
Phase
Phase 3
Modality
small_molecule
Status
active

Clinical trials